ANTITHROMBOTIC THERAPY GUIDE: *Level of Intensity Based on Indication*

Patient: _____ Laboratory: _____

Diagnosis: _____ Target INR: _____

Antithrombotic Therapy Selection: Level of Intensity Based on Indication

CLINICAL SCENARIO	THERAPY
❑ Atrial fibrillation: ❍ Lone Atrial Fibrillation ❍ Idiopathic/Degenerative ❍ HTN Heart Disease ❍ Cardiomyopathy/LV dysfunction ❍ Valvular Heart Disease ❍ Hyperthyroidism ❍ Post-operative(Thoracic/Cardiac) ❍ Other:_____	❑ NOAC: ❍ Apixaban 5 mg BID ❍ Apixaban 2.5 mg BID ❍ Dabigatran150 mg BID ❍ Dabigatran 110 mg BID ❍ Rivaroxaban 20 mg OD ❍ Rivaroxaban 15 mg OD ❑ Low dose (LD) VKA* (INR 2.0-3.0) ❑ LD ASA ❑ Clopidogrel
❑ Mechanical Prosthetic Valve	Consider adding LD ASA to VKA if low risk of bleeding
❑ **Long term anticoagulation** ❍ Aortic mechanical valve ❍ Mechanical mitral valve ❍ Dual mechanical AV/MV	 Low dose (LD) VKA* (INR 2.5: range 2.0-3.0) Medium dose (MD) VKA* (INR 3.0: range 2.5-3.5) Medium dose (MD) VKA* (INR 3.0: range 2.5-3.5)
❑ Concomitant atherosclerosis	Add LD ASA or Clopidogrel
❑ Bioprosthetic valve	
❍ Routine: patient in NSR	LD VKA* X 3 months then LD ASA
❑ AF, LA thrombus, Thromboembolism	LD VKA* (INR 2.5: range 2.0-3.0)

*VKA = Vitamin K antagonist

DATE D/M/Y	INR	WARFARIN DOSE mg	CALLED ✓	NEXT CHECK	BILLED ✓	WT LBS/KG	CR/ EGFR	TIA/CVA PVE	BLEEDING (SITE/MAJOR/MINOR)	HGB	LFTs

© Continuing Medical Implementation® Inc. April 2014